Senores Pharmaceuticals Ltd.
NSE: SENORES · Pharmaceuticals
Snapshot
Unlock Senores Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Senores Pharmaceuticals Limited is an Ahmedabad-based company engaged in the development, manufacture, and trade of a diverse range of pharmaceutical products. Its portfolio spans therapeutic categories including analgesics, antibiotics, cardiovascular, neurology, and anti-diabetic solutions, alongside management and consultancy services.
Business Model
The company generates revenue through the sale and distribution of pharmaceutical formulations and generic drugs across domestic and international markets. It further diversifies its income streams by providing professional management and consultancy services within the pharmaceutical sector.
Growth Outlook
Growth is driven by the company's expansion into international markets including the United States, United Kingdom, and Canada. Continued focus on a broad therapeutic product range positions the firm to capture demand across multiple healthcare segments.
- Incorporation Year:2017
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, which could impact product approvals and market access.
- Market Competition. Intense competition in the generic pharmaceutical sector may exert pressure on pricing and profit margins.
- Geopolitical and Currency Risk. Operating across multiple international jurisdictions exposes the company to fluctuations in foreign exchange rates and changing trade policies.
- Supply Chain Vulnerability. Dependence on global supply chains for raw materials and active pharmaceutical ingredients poses risks to manufacturing continuity.
Start your research today
Unlock AI insights, financials, peers and live data on Senores Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹722 Cr
TTM · consolidated
NET PROFIT
₹137 Cr
TTM · consolidated
EPS
₹30.71
TTM · consolidated
RETURN ON EQUITY
15.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
18.3%
TTM · consolidated
P/E
36.5×
Q2 FY27 · consolidated
EV/EBITDA
22.5x
Q2 FY27 · consolidated
EBITDA MARGIN
34.1%
TTM · consolidated
NET PROFIT MARGIN
19.0%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.4x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Senores Pharmaceuticals Ltd.SENORES | ₹5,156 Cr | 36.5× | 22.48 | 39.7% | 34.1% | 15.1% | 18.3% | +45.2% |
Sun Pharma Advanced Research Company LimitedSPARC | ₹5,682 Cr | 3.6× | 3.80 | 2855.8% | 86.0% | 282.4% | 235.1% | +29.5% |
IOL Chemicals and Pharmaceuticals LimitedIOLCP | ₹5,291 Cr | 26.0× | 14.28 | 26.8% | 13.9% | 11.1% | 14.9% | +94.8% |
Orchid Pharma LimitedORCHPHARMA | ₹5,074 Cr | 526.3× | 81.55 | 10.8% | 7.1% | 0.7% | 1.5% | +16.7% |
Gujarat Themis Biosyn Ltd.GUJTHEM | ₹4,811 Cr | 140.0× | 58.65 | 17.5% | 48.8% | 18.2% | 19.8% | -20.5% |
SMS Pharmaceuticals LimitedSMSPHARMA | ₹4,721 Cr | 44.9× | 27.64 | 10.2% | 20.3% | 14.4% | 15.5% | +76.5% |
As of Q2 FY27
Financials
Senores Pharmaceuticals Ltd.
NSE: SENORES · Pharmaceuticals
Snapshot
Unlock Senores Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Senores Pharmaceuticals Limited is an Ahmedabad-based company engaged in the development, manufacture, and trade of a diverse range of pharmaceutical products. Its portfolio spans therapeutic categories including analgesics, antibiotics, cardiovascular, neurology, and anti-diabetic solutions, alongside management and consultancy services.
Business Model
The company generates revenue through the sale and distribution of pharmaceutical formulations and generic drugs across domestic and international markets. It further diversifies its income streams by providing professional management and consultancy services within the pharmaceutical sector.
Growth Outlook
Growth is driven by the company's expansion into international markets including the United States, United Kingdom, and Canada. Continued focus on a broad therapeutic product range positions the firm to capture demand across multiple healthcare segments.
- Incorporation Year:2017
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, which could impact product approvals and market access.
- Market Competition. Intense competition in the generic pharmaceutical sector may exert pressure on pricing and profit margins.
- Geopolitical and Currency Risk. Operating across multiple international jurisdictions exposes the company to fluctuations in foreign exchange rates and changing trade policies.
- Supply Chain Vulnerability. Dependence on global supply chains for raw materials and active pharmaceutical ingredients poses risks to manufacturing continuity.
Start your research today
Unlock AI insights, financials, peers and live data on Senores Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹722 Cr
TTM · consolidated
NET PROFIT
₹137 Cr
TTM · consolidated
EPS
₹30.71
TTM · consolidated
RETURN ON EQUITY
15.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
18.3%
TTM · consolidated
P/E
36.5x
Q2 FY27 · consolidated
EV/EBITDA
22.5x
Q2 FY27 · consolidated
EBITDA MARGIN
34.1%
TTM · consolidated
NET PROFIT MARGIN
19.0%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.4x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
As of Q2 FY27